Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Artemisinin Supplier Overtakes Novartis’ Export

This article was originally published in PharmAsia News

Executive Summary

According to the latest statistics from China's Chamber of Commerce of Medicines & Health Products Importers & Exporters (CCCMPHIE), total local export of Artemisinin products reached $40 million in the first three quarters of last year. Guilin Pharmaceutical, a subsidiary of Shanghai Fosun Pharmaceutical, ranked one, toppling incumbent supplier Beijing Novartis. However, Novartis still dominates the global market, with most of its product made in the U.S. and only 10 percent contributed by Beijing Novartis. The present competition and uneven product standards have caused pricing of domestic Artemisinin to plunge. The Ministry of Commerce and related organizations are formulating regulations on Artemisinin export to bring more structure to the industry. (Click here for more)

You may also be interested in...

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts